See other companies on Welcome to the Jungle
Seer
Empowering the scientific community through the power of proteomics
- 101-200 employees
- B2B
- Enterprise
- Science
- Biotechnology
- Redwood Shores, Redwood City, CA
Jump to section
Company mission
To decode the secrets of the proteome to improve human health.
Our take
Seer offers tools and solutions that provide unbiased, deep, rapid and large-scale proteomics in the field of biotechnology. More specifically, Seer's life sciences and health data platform helps detect life-threatening diseases before symptoms start to show. The company claims to be able to analyze protein composition in a comparable way to sequencing machines ‘reading’ strands of DNA.
Seer has grown rapidly: the company went public in 2020 after being founded in 2017, and enjoys strong financial backing that has helped it launch a varied range of proteomics products.
Seer faces competition from the likes of Nautilus and Illumina, a multibillion giant in the sequencing world, who have a sub-division dedicated to proteomics. However, Seer has featured on the Deloittes Fast500 2023 and won multiple awards for its innovative product, putting it in good stead to grow rapidly.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- E-Verify Participation Notice
- Family and Medical Leave Act
- Pay Transparency Nondiscrimination Provision
- Anti-Discrimination Notice/Right to Work
Funding (last 2 of 5 rounds)
Jul 2020
$55m
SERIES D
Dec 2019
$55m
SERIES D
Total funding: $169.5m
Leadership
Omid Farokhzad
(Chair and CEO)Extensive experience as Chair, Director and Co-founder across multiple companies and technology platforms. Also a graduate of Harvard Medical School.
Articles
Jobs (3)
Marketing
Finance, Legal & Compliance
Sales & Account Management